Quality of Life in elderly patients with cancer

由 Perrone Francesco, Di Maio Massimo
出版 2003-09-01

Quality of Life in elderly patients with cancer

由 Di Maio, Massimo, Perrone, Francesco
出版 2003

A review of guidelines for lung cancer

由 Bironzo, Paolo, Di Maio, Massimo
發表在 J Thorac Dis (2018)

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

由 Metro, Giulio, Di Maio, Massimo
發表在 Transl Lung Cancer Res (2018)

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

由 Metro, Giulio, Di Maio, Massimo
發表在 Transl Lung Cancer Res (2018)

The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer

由 Di Maio, Massimo, Scagliotti, Giorgio Vittorio
發表在 Transl Lung Cancer Res (2015)

Real‐World Evidence in Oncology: Opportunities and Limitations

由 Di Maio, Massimo, Perrone, Francesco, Conte, Pierfranco
發表在 Oncologist (2019)

Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials

由 Facchinetti, Francesco, Di Maio, Massimo, Tiseo, Marcello
發表在 Cancers (Basel) (2020)

Raising the bar for enthusiasm when looking at results of randomized phase II trials—the case of sunitinib in small-cell lung cancer

由 Di Maio, Massimo, Bironzo, Paolo, Scagliotti, Giorgio Vittorio
發表在 Transl Lung Cancer Res (2016)

Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence

由 De Luca, Emmanuele, Marino, Donatella, Di Maio, Massimo
發表在 Cancer Manag Res (2020)

The KEY for chemo-immunotherapy combination: taking NOTEs from squamous cell lung cancer

由 Reale, Maria Lucia, De Luca, Emmanuele, Di Maio, Massimo
發表在 Transl Lung Cancer Res (2020)

COVID-19 Emergency and the Need to Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice

由 Marandino, Laura, Necchi, Andrea, Aglietta, Massimo, Di Maio, Massimo
發表在 JCO Oncol Pract (2020)

First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis

由 Facchinetti, Francesco, Di Maio, Massimo, Perrone, Fabiana, Tiseo, Marcello
發表在 Transl Lung Cancer Res (2021)

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-...

由 Addeo, Alfredo, Banna, Giuseppe Luigi, Metro, Giulio, Di Maio, Massimo
發表在 Front Oncol (2019)

Second-line treatment options in hepatocellular carcinoma

由 Marino, Donatella, Zichi, Clizia, Audisio, Marco, Sperti, Elisa, Di Maio, Massimo
發表在 Drugs Context (2019)

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis

由 Guaitoli, Giorgia, Tiseo, Marcello, Di Maio, Massimo, Friboulet, Luc, Facchinetti, Francesco
發表在 Transl Lung Cancer Res (2021)

Selection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase Inhibitors

由 Zwitter, Matjaz, Rossi, Antonio, Di Maio, Massimo, Perme, Maja Pohar, Lopes, Gilberto
發表在 Radiol Oncol (2017)

BRAF-mutated metastatic colorectal cancer between past and future

由 Cremolini, Chiara, Di Maio, Massimo, Petrelli, Fausto, Berenato, Rosa, Loupakis, Fotios, Pietrantonio, Filippo
發表在 Br J Cancer (2015)

Coronavirus: Older Persons With Cancer in Italy in the COVID-19 Pandemic

由 Fratino, Lucia, Procopio, Giuseppe, Di Maio, Massimo, Cinieri, Saverio, Leo, Silvana, Beretta, Giordano
發表在 Front Oncol (2020)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions

由 Tucci, Marcello, Zichi, Clizia, Buttigliero, Consuelo, Vignani, Francesca, Scagliotti, Giorgio V, Di Maio, Massimo
發表在 Onco Targets Ther (2018)